NCT02303873View on ClinicalTrials.gov

Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta

PHASE4CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

August 31, 2014

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

Alendronate

Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).

All Listed Sponsors
collaborator

National Natural Science Foundation of China

OTHER_GOV

lead

Peking Union Medical College Hospital

OTHER

NCT02303873 - Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta | Biotech Hunter | Biotech Hunter